文献速递临床试验与 GCP

BRONCHIOLE研究方案:COPD患者使用β受体阻滞剂的随机对照试验

Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) - Study protocol from a randomized controlled trial.
PubMed 文献 · Trials · 2020-01-30

BRONCHIOLE是一项开放标签、多中心、前瞻性随机对照试验,计划纳入1700例无确诊心血管疾病的COPD患者,随机接受标准COPD治疗联合美托洛尔目标剂量100mg/日或仅标准COPD治疗,主要终点为死亡、COPD急性加重和心血管事件的复合终点,随访1年。

要点

  • 旨在验证无心血管疾病的COPD患者使用β受体阻滞剂能否降低1年死亡、急性加重或心血管事件复合风险。
  • 美托洛尔目标剂量为100mg/日,与标准COPD治疗联合使用。
  • 排除缺血性心脏病、左心衰竭、脑血管病、严重肢体缺血及房颤/房扑患者。

核心结论

  • BRONCHIOLE试验旨在填补无确诊心血管疾病的COPD患者使用β受体阻滞剂缺乏随机对照证据的空白。

研究设计与样本

  • 开放标签、多中心、前瞻性随机对照试验,计划随机分配1700例COPD患者。
  • 干预组接受标准COPD治疗联合美托洛尔目标剂量100mg/日,对照组仅接受标准COPD治疗。
  • 随访包括入选访视、1个月美托洛尔滴定访视、6个月电话随访和1年最终访视。

关键数值与推荐

  • 主要终点为死亡、COPD急性加重和心血管事件的复合终点,评估1年风险。
  • 主要排除标准包括缺血性心脏病、左心衰竭、脑血管病、严重肢体缺血及房颤/房扑。
  • 试验注册号NCT03566667,注册日期2018年6月25日。

临床怎么用

  • 目前尚无随机对照证据支持无心血管疾病的COPD患者常规使用β受体阻滞剂,需等待BRONCHIOLE试验结果。

局限性

  • 研究方案阶段,尚无结果数据报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational studies indicate that beta-blockers are associated with a reduced risk of exacerbation and mortality in patients with chronic obstructive pulmonary disease (COPD) even without overt cardiovascular disease, but data from randomized controlled trials (RCT) are lacking. The aim of this RCT is to investigate whether beta-blocker therapy in patients with COPD without diagnosed cardiovascular disease is associated with a decreased 1-year risk of the composite endpoint of death, exacerbations, or cardiovascular events. METHODS: The Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) study is an open-label, multicentre, prospective RCT. A total of 1700 patients with COPD will be randomly assigned to either standard COPD care and metoprolol at a target dose of 100 mg per day or to standard COPD care only. The primary endpoint is a composite of death, COPD exacerbations, and cardiovascular events. Major exclusion criteria are ischemic heart disease, left-sided heart failure, cerebrovascular disease, critical limb ischemia, and atrial fibrillation/flutter. Study visits are an inclusion visit, a metoprolol titration visit at 1 month, follow-up by telephone at 6 months, and a final study visit after 1 year. Outcome data are obtained from medical history and record review during study visits, as well as from national registries. DISCUSSION: BRONCHIOLE is a pragmatic randomized trial addressing the potential of beta-blockers in patients with COPD. The trial is expected to provide relevant clinical data on the efficacy of this treatment on patient-related outcomes in patients with COPD. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03566667. Registered on 25 June 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sundh J, Magnuson A, Montgomery S, et al. Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) - Study protocol from a randomized controlled trial. Trials. 2020. PMID: 32000825. doi:10.1186/s13063-019-3907-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。